Analyst Reco. Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-04-24 pm EDT			5-day change	1st Jan Change
7.370 ^USD	+1.10%		-3.53%	-46.24%

Apr. 21	Myriad Genetics, Inc. Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations After GeneSight Testing	CI
Apr. 09	Guggenheim Downgrades Myriad Genetics to Neutral From Buy	MT

Analyst Reco.

Guggenheim Downgrades Myriad Genetics to Neutral From Buy	Apr. 09	MT
Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50	Mar. 12	MT
UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating	Feb. 25	MT
Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30	Dec. 09	MT
Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	Nov. 18	MT
Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target	24-09-19	MT
Morgan Stanley Initiates Myriad Genetics at Equalweight	24-09-19	MT
Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target	24-08-28	MT
Scotiabank Initiates Myriad Genetics at Sector Outperform	24-06-27	MT
Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating	24-05-13	MT
Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating	24-01-29	MT
BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating	24-01-29	MT
Wells Fargo Initiates Myriad Genetics at Equalweight Rating With $20 Price Target	23-12-19	MT
Wolfe Research Initiates Myriad Genetics With Outperform Rating With $28 Price Target	23-12-13	MT
BofA Securities Trims Price Target on Myriad Genetics to $18 From $21, Maintains Underperform Rating	23-10-20	MT
JPMorgan Adjusts Myriad Genetics' Price Target to $17 From $18, Keeps Underweight Rating	23-08-07	MT
Goldman Sachs Adjusts Price Target on Myriad Genetics to $28 From $25, Maintains Buy Rating	23-07-21	MT
Goldman Sachs Upgrades Myriad Genetics to Buy From Sell, Raises Price Target to $25 From $18	23-05-23	MT
Analyst recommendations: Chevron, Deere & Co, Nvidia, Steel Dynamics...	23-05-23
Jefferies Raises Myriad Genetics' Price Target to $22 From $19, Hold Rating Kept	23-05-04	MT
Morningstar Downgrades Myriad Genetics to Sell From Hold, $18.50 Price Target	23-05-04	MT
Goldman Sachs Cuts Myriad Genetics' Price Target to $18 From $20, Sell Rating Kept	23-05-04	MT
Stephens Adjusts Price Target on Myriad Genetics to $24 From $17, Maintains Equal-Weight Rating	23-03-06	MT
Raymond James Adjusts Price Target on Myriad Genetics to $27 From $25, Maintains Outperform Rating	23-03-03	MT
Raymond James Upgrades Myriad Genetics to Outperform From Market Perform, Price Target is $25	23-01-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Analyst Reco.

Filters